1. All Products
  2. DVAC - Vaccines
  3. VACCINE PNEUMOC. CONJ. PCV13, 1dose,multid.v (non-hum.mech.)
Public Pricelist

VACCINE PNEUMOC. CONJ. PCV13, 1dose,multid.v (non-hum.mech.)

https://medicalguidelines.msf.org/en/node/971
https://unicat.msf.org/cat/product/77443
STD DVACVPCV13VDN

Valid Article

The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
19.3 - Vaccines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J07AL02
Anatomical Therapeutic Chemical Classification according to WHOCC
P
The order of this product needs to be justified and is only acceptable under certain conditions.
0208
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

VACCINE PNEUMOCOCCAL CONJUGATE PCV13

CAUTION

The multidose vaccines are worded and codified by unit (= 1 dose) to make the order easier.

Therapeutic Action

13-valent polysaccharide conjugated vaccine

Indications

Active immunisation against invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae, in children from 6 weeks of age.

Most countries have introduced PCV vaccine into their routine immunisation activities.

Beyond routine immunisation, MSF recommends PCV in particular for children with severe acute malnutrition, children born to HIV-positive mothers and people with functional or surgical asplenia.

The choice between Pneumosil® (PCV-10 SII), Synflorix® (PCV-10-GSKI) and Prevenar® (PCV-13-Pfizer) vaccine will depend on which vaccine is introduced and registered in the country where it will be used.

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Prevenar® (PCV-13-Pfizer).

Suspension in a liquid form. Shake well before use to homogenise the suspension.

Must be given as IM injection into the anterolateral part of the thigh in children < 2 years and into the deltoid muscle in children ≥ 2 years.

Two different codes depending on the context and intended use:

  • DVACVPC13VD: humanitarian mechanism with WHO approval for emergencies
  • DVACVPC13VDN: non-humanitarian mechanism and other indications (asplenia)

Orders are always done in number of doses and not in number of vials! (See Preliminary remarks on Vaccines)

Precautions for Use

Do not administer into the gluteal muscle.

As with all injectable vaccines and/or immunoglobulins, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the product.

Storage

  • Keep refrigerated between 2ºC and 8ºC - Protect from sunlight
  • Do not freeze.
  • After vial opening, the PCV13 vaccine, kept between 2ºC and 8ºC, may be used in subsequent immunisation sessions for up to 28 days.
  • The vaccine vial monitor (VVM) is mandatory on each vaccine.

(Cf Introduction: Thermosensitive products)